UY36140A - Formulación de ceritinib - Google Patents

Formulación de ceritinib

Info

Publication number
UY36140A
UY36140A UY0001036140A UY36140A UY36140A UY 36140 A UY36140 A UY 36140A UY 0001036140 A UY0001036140 A UY 0001036140A UY 36140 A UY36140 A UY 36140A UY 36140 A UY36140 A UY 36140A
Authority
UY
Uruguay
Prior art keywords
composition
ceritinib
tablet
binder
formulation
Prior art date
Application number
UY0001036140A
Other languages
English (en)
Inventor
Breulles Sebastian
Ensslin Simon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53298568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY36140(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY36140A publication Critical patent/UY36140A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

La presente descripción se refiere a una nueva composición farmacéutica que comprende Ceritinib. En particular se dirige a la tableta que se prepara por granulación húmeda, en donde se utiliza povidona como aglutinante. Una característica adicional de la composición es que el fármaco y el aglutinante forman la fase interna, mientras que todos los otros excipientes se añaden en forma de polvo como una fase externa. De esta manera, se evita la adherencia de la composición y se puede lograr una dureza suficiente de la tableta.
UY0001036140A 2014-05-29 2015-05-27 Formulación de ceritinib UY36140A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462004359P 2014-05-29 2014-05-29

Publications (1)

Publication Number Publication Date
UY36140A true UY36140A (es) 2016-01-08

Family

ID=53298568

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036140A UY36140A (es) 2014-05-29 2015-05-27 Formulación de ceritinib

Country Status (27)

Country Link
US (4) US20170112834A1 (es)
EP (1) EP3148513B1 (es)
JP (3) JP6679578B2 (es)
KR (1) KR20170008239A (es)
CN (1) CN106456640B (es)
AR (1) AR100625A1 (es)
AU (3) AU2015265470A1 (es)
BR (1) BR112016027580A8 (es)
CA (1) CA2948291A1 (es)
CL (1) CL2016003047A1 (es)
DK (1) DK3148513T3 (es)
EA (1) EA036922B1 (es)
EC (1) ECSP16096826A (es)
ES (1) ES2792574T3 (es)
HU (1) HUE048950T2 (es)
IL (1) IL248835B (es)
MX (1) MX373624B (es)
PE (1) PE20170313A1 (es)
PH (1) PH12016502272A1 (es)
PL (1) PL3148513T3 (es)
PT (1) PT3148513T (es)
SG (1) SG11201609208UA (es)
SI (1) SI3148513T1 (es)
TN (1) TN2016000484A1 (es)
TW (1) TWI721946B (es)
UY (1) UY36140A (es)
WO (1) WO2015181739A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015265470A1 (en) 2014-05-29 2016-11-24 Novartis Ag Ceritinib formulation
CN106176752B (zh) * 2015-05-07 2020-06-23 石药集团中奇制药技术（石家庄）有限公司 色瑞替尼药物组合物
CN109381440A (zh) * 2018-11-15 2019-02-26 威海贯标信息科技有限公司 一种艾乐替尼组合物
CN113244236B (zh) * 2021-06-01 2023-02-03 上海市第一人民医院 色瑞替尼在制备治疗甲状腺相关眼病的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632778A (en) * 1970-06-10 1972-01-04 Hoffmann La Roche Tablets containing l-dopa
AU2007223278A1 (en) * 2006-03-06 2007-09-13 Wyeth Tablet formulations and processes
US20080175901A1 (en) 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20090239920A1 (en) 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
BRPI0720264B1 (pt) * 2006-12-08 2022-03-03 Novartis Ag Compostos e composições como inibidores de proteína cinase
EP2311807B1 (en) * 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
ES2377869T3 (es) * 2008-09-04 2012-04-02 Cargill, Incorporated Fabricación de comprimidos de eritritol
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
EP2467029A1 (en) 2009-08-18 2012-06-27 Cargill, Incorporated Tabletting of erythritol and isomalt
JP5596799B2 (ja) * 2010-05-11 2014-09-24 田辺三菱製薬株式会社 カナグリフロジン含有錠剤
JP2013536694A (ja) 2010-09-07 2013-09-26 カーギル インコーポレイテッド 凝固糖アルコール混合物
AU2015265470A1 (en) 2014-05-29 2016-11-24 Novartis Ag Ceritinib formulation

Also Published As

Publication number Publication date
TN2016000484A1 (en) 2018-04-04
ES2792574T3 (es) 2020-11-11
TW201613580A (en) 2016-04-16
CN106456640A (zh) 2017-02-22
AU2019232937B2 (en) 2020-10-15
CA2948291A1 (en) 2015-12-03
EA036922B1 (ru) 2021-01-15
DK3148513T3 (da) 2020-05-25
EP3148513B1 (en) 2020-02-26
ECSP16096826A (es) 2018-04-30
CL2016003047A1 (es) 2017-04-07
AU2015265470A1 (en) 2016-11-24
US12357630B2 (en) 2025-07-15
SG11201609208UA (en) 2016-12-29
AU2019232937A1 (en) 2019-10-10
BR112016027580A8 (pt) 2021-06-29
PH12016502272A1 (en) 2017-02-06
AR100625A1 (es) 2016-10-19
JP2020114834A (ja) 2020-07-30
BR112016027580A2 (pt) 2017-08-15
PE20170313A1 (es) 2017-04-18
PT3148513T (pt) 2020-05-27
MX2016015736A (es) 2017-03-16
EA201692310A1 (ru) 2017-04-28
JP2017520619A (ja) 2017-07-27
US20210154194A1 (en) 2021-05-27
AU2018203007B2 (en) 2019-07-18
US20200009141A1 (en) 2020-01-09
WO2015181739A1 (en) 2015-12-03
IL248835A0 (en) 2017-01-31
MX373624B (es) 2020-05-22
IL248835B (en) 2020-05-31
PL3148513T3 (pl) 2020-08-24
HUE048950T2 (hu) 2020-09-28
AU2018203007A1 (en) 2018-05-17
US11000523B2 (en) 2021-05-11
EP3148513A1 (en) 2017-04-05
CN106456640B (zh) 2021-05-14
JP7084955B2 (ja) 2022-06-15
JP2022078236A (ja) 2022-05-24
KR20170008239A (ko) 2017-01-23
JP6679578B2 (ja) 2020-04-15
US20190022095A1 (en) 2019-01-24
SI3148513T1 (sl) 2020-07-31
US20170112834A1 (en) 2017-04-27
TWI721946B (zh) 2021-03-21

Similar Documents

Publication Publication Date Title
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
LT2986304T (lt) Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
CU20160006A7 (es) Derivados de piperidinil-indol como inhibidores de factor de complemento b
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
HUE047782T2 (hu) Gyógyászatilag aktív vegyületek és alkalmazási eljárásaik
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
PT3357491T (pt) Composição farmacêutica para distribuir um fármaco aniónico
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
DK3116491T3 (da) Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
MX389178B (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
MX2015012416A (es) Compuestos heterociclicos y sus usos.
CR20150096A (es) Formulaciones de trans-clomifeno y usos de los mismas
CR20160139A (es) Sistemas y métodos para el suministro sin disolventes de compuestos volátiles
HK1231390A1 (zh) 用於局部给药的药用组合物
HUE049437T2 (hu) Hatóanyagként heterociklusos diamino-karboxamid vegyületet tartalmazó gyógyászati készítmény
DK2981258T3 (da) Farmaceutiske formuleringer til subkutan indgivelse af furosemid
BR112018002283A2 (pt) Composição para administração tópica a um sujeito, e, formulação tópica
UY36140A (es) Formulación de ceritinib
MX2015012318A (es) Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.
GT201300032A (es) Composicion farmaceutica de liberacion prolongada de trimetazidina
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
CL2016000397A1 (es) Tratamiento contra el cáncer

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220620